OW29 documents

20/06/2025

Panitumumab supplementary tables CIC removed for website OW29

20/06/2025

Panitumumab rechallenge mCRC ESR CIC removed for website OW29

20/06/2025

Panitumumab RASWT mCRC final recommendation with start_stop criteria (OW29)

20/06/2025

OWMAG decision rationale panitumumab mCRC final OW29

20/06/2025

EqHIA Panitumumab for RASWT mCRC assessment 2025 OW29

20/06/2025

Appendix 2.b. Cost of regorafenib followed by best supportive care and Appendix 2.c. Cost of best supportive care for fifth-line 

20/06/2025

Appendix 2.a. Cost of trifluridine-tipiracil and bevacizumab followed by best supportive care

20/06/2025

Appendix 1 PRISMA flow diagram (43)

20/06/2025

Table 13. Budget impact for four months panitumumab as fourth line treatment

20/06/2025

Table 12. Budget impact for four months panitumumab as third line treatment

20/06/2025

Table 11. Net resource costs for upper and lower patient number estimates for panitumumab and comparator treatments

20/06/2025

Table 10. Cost of panitumumab and comparators in Wales (per patient)

20/06/2025

Table 9. Severity modifier considerations for One Wales Medicines Assessment Group (OWMAG)

20/06/2025

Table 8. Examples of medicine acquisition costs 

20/06/2025

Table 7. Potential QALY by treatment line 

20/06/2025

Table 6. Threshold analysis

20/06/2025

Table 5. Fourth-line and Fifth-line cost consequence analyses

20/06/2025

Table 4. Base case analysis 

20/06/2025

Table 3. Progression free survival, overall survival and adverse events

20/06/2025

Table 2. Comparator costs